ロード中...
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuz...
保存先:
| 出版年: | Cells |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7140687/ https://ncbi.nlm.nih.gov/pubmed/32245149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030768 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|